UPDATED May 21, 2024
Companys with strong funding and high growth potential
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
PTN | US$1.85 | -17.4% | -17.6% | US$32.9m | US$7.73 | PS5.7x | E63.0% | n/a | Pharmaceuticals & Biotech | ||
1AE | €334.00 | 0.4% | -13.6% | €19.6b | €440.65 | PS14.7x | E60.1% | n/a | Pharmaceuticals & Biotech | ||
6IB | HK$4.48 | -3.4% | -4.3% | HK$62.2b | HK$6.48 | PS9.3x | E50.8% | n/a | Pharmaceuticals & Biotech | ||
YDO1 | US$213.90 | 10.6% | -18.0% | US$4.9b | US$320.96 | PB6.1x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
OL0 | kr8.42 | -0.7% | 22.7% | kr1.6b | kr10.62 | PS9x | E99.0% | n/a | Pharmaceuticals & Biotech | ||
4LN2 | US$5.55 | 23.7% | 30.9% | US$198.5m | US$17.47 | PS7.3x | E66.2% | n/a | Pharmaceuticals & Biotech | ||
PH4 | HK$0.15 | 18.3% | -56.0% | HK$1.7b | n/a | PS3.4x | E56.9% | n/a | Pharmaceuticals & Biotech | ||
78F0 | US$6.00 | 0% | n/a | US$28.3m | US$6.02 | PS45.4x | E57.2% | n/a | Pharmaceuticals & Biotech | ||
B00 | US$6.80 | 0% | -80.4% | US$1.6m | n/a | PB0.7x | E65.8% | n/a | Pharmaceuticals & Biotech | ||
LWB1 | AU$1.87 | 0% | -69.2% | AU$986.2m | AU$2.38 | PS86.9x | E64.4% | n/a | Pharmaceuticals & Biotech | ||
UXI | US$3.26 | 0% | -58.6% | US$3.2m | US$218.47 | PS8.2x | E52.2% | n/a | Pharmaceuticals & Biotech | ||
9H4 | UK£0.23 | -19.1% | -59.3% | UK£6.3m | UK£2.45 | PS173.7x | E88.7% | n/a | Pharmaceuticals & Biotech | ||
XUP | €3.69 | 10.6% | -3.8% | €184.4m | €9.33 | PS5.3x | E54.7% | n/a | Pharmaceuticals & Biotech | ||
7AY1 | US$9.03 | 9.9% | 10.1% | US$288.6m | US$25.89 | PS3257.8x | E68.5% | n/a | Pharmaceuticals & Biotech | ||
0QF | US$132.60 | 13.2% | 8.6% | US$55.1b | US$127.82 | PS10.7x | E68.8% | n/a | Pharmaceuticals & Biotech | ||
6XP | kr5.00 | 0% | n/a | kr1.4b | n/a | PB2.8x | E124.4% | n/a | Pharmaceuticals & Biotech | ||
P7N1 | €52.00 | 0% | 217.1% | €1.3b | n/a | PB4.9x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
VPA1 | US$13.77 | 0.7% | 358.7% | US$521.4m | US$13.77 | PS5.5x | E123.0% | n/a | Pharmaceuticals & Biotech | ||
137 | US$3.57 | 5.2% | -60.0% | US$239.4m | US$8.39 | PB2.1x | E61.1% | n/a | Pharmaceuticals & Biotech | ||
NV4 | US$2.94 | 1.4% | 122.7% | US$113.3m | US$13.57 | PB12.8x | E61.8% | n/a | Pharmaceuticals & Biotech | ||
GON | US$3.39 | -1.5% | 16.6% | US$2.2b | US$5.55 | PS4220.4x | E64.9% | n/a | Pharmaceuticals & Biotech | ||
4XC1 | US$10.70 | -2.7% | 10.9% | US$501.2m | US$27.46 | PB5.5x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
1ZL | US$18.10 | -7.7% | -39.3% | US$2.1b | US$46.47 | PS6.8x | E66.5% | n/a | Pharmaceuticals & Biotech | ||
9LB | US$39.20 | -3.4% | -36.8% | US$8.3b | US$77.74 | PS22.8x | E62.7% | n/a | Pharmaceuticals & Biotech |